Skip to content

Nasal Lavage IL-4 and IL-13 in Cystic Fibrosis-Related Chronic Rhinosinusitis: Associations With Disease Severity and Potential Implications for Targeted Therapies.

Aug 2026 · International Forum of Allergy and Rhinology · 0 citations · 28 references
Medicine

TL;DR

CF-associated CRS exhibits a heterogeneous inflammatory profile in which type-2 cytokines, particularly IL-4 and IL-13, are linked to disease severity and olfactory dysfunction, and Nasal lavage cytokines may represent promising compartment-specific biomarkers to support inflammatory endotyping and targeted therapeutic strategies.

Abstract

Background

Chronic rhinosinusitis (CRS) is highly prevalent in patients with cystic fibrosis (CF) and has traditionally been considered a predominantly neutrophilic condition. Emerging evidence, however, suggests that type-2 inflammatory pathways may contribute to disease heterogeneity. Data linking local inflammatory mediators with objective sinonasal disease severity and olfactory dysfunction in CF-associated CRS remain limited.

Methods

In this cross-sectional study, 42 adults with CF-associated CRS (22 with nasal polyps and 20 without) underwent assessment of disease severity using the nasal polyp score (Meltzer classification) (NPS-MS), modified Lund-Kennedy score (mLKS), and Lund-Mackay score (LMS), together with olfactory testing (Sniffin' Sticks Identification Test) and quality-of-life evaluation (22-item Sinonasal Outcome Test [SNOT-22]). Nasal lavage concentrations of IL-4, IL-13, and IL-8 were quantified by ELISA.

Results

IL-4 and IL-13 were significantly associated with objective measures of sinonasal disease severity, including NPS-MS and LMS (all p < 0.05), whereas IL-8 did not show consistent associations with disease severity. In multivariable models, IL-4 remained independently associated with mLKS (p = 0.025), LMS (p = 0.047), and olfactory dysfunction (p = 0.002). IL-13 was primarily associated with NPS-MS (p = 0.007) and LMS (p = 0.005). Lung transplantation modified cytokine-severity relationships. Exploratory analyses showed lower IL-4 levels in elexacaftor/tezacaftor/ivacaftor-treated patients (p = 0.036), with no significant effects for IL-8 or IL-13.

Conclusions

CF-associated CRS exhibits a heterogeneous inflammatory profile in which type-2 cytokines, particularly IL-4 and IL-13, are linked to disease severity and olfactory dysfunction. Nasal lavage cytokines may represent promising compartment-specific biomarkers to support inflammatory endotyping and targeted therapeutic strategies.

View source

Similar papers

Open access Sep 2026

Exploring The Relationship between FOXP3⁺ Regulatory T Cells, Eosinophilia, and Disease Severity in Chronic Rhinosinusitis with Nasal Polyps

INTRODUCTION: Chronic Rhinosinusitis (CRS) is a common condition causing a significant worldwide burden, affecting 5%-12% of the general population. The immunoregulatory mechanisms underlying eosinophilic and non-eosinophilic CRS with polyps (CRSwNP) remain incompletely understood, particularly with respect to regulato...

Gnanasoundari Gokulakannan, N. A. Che Jalil, Ramlah Kadir et al. · 0 citations
Case report Open access Sep 2026

Case Report: Olfactory loss as the sentinel manifestation of type 2 chronic rhinosinusitis without polyps: response to IL-4Rα inhibition with stapokibart - a case series

Chronic rhinosinusitis without nasal polyps (CRSsNP) is traditionally associated with type 1 inflammation, but emerging evidence reveals a subset of patients with a type 2 endotype driven by IL-4 and IL-13, often presenting with prominent olfactory dysfunction and responding poorly to conventional therapy. We report th...

Hua Cai, Tao Zhou, Juan-Juan Hu et al. · 0 citations
Review Open access Oct 2026

Targeting upstream alarmins (TSLP, IL-33, IL-25): a new frontier in treating type 2 chronic rhinosinusitis with nasal polyps

Chronic rhinosinusitis with nasal polyps (CRSwNP) affects 1%-4% of adults globally and imposes a substantial burden on quality of life. Despite endoscopic surgery, topical corticosteroids, and systemic glucocorticoids, postoperative recurrence exceeds 54% at five years. Even with the advent of biologics targeting downs...

Shu-Huan Li · 0 citations
Oct 2026

Efficacy of Dupilumab for Patients with Chronic Rhinosinusitis without Nasal Polyps: a Randomized Double-Blind Placebo Controlled Phase II Study.

The observed trend toward enhanced benefit in T2-high patients supports the potential for endotype-directed therapy and underscores the need for larger studies to evaluate the role of T2-targeted biologics in CRSsNP management.

J. Tversky, Andrew P. Lane, John T. Schroeder et al. · 0 citations

The impact of air quality on tissue eosinophilia and the severity of chronic rhinosinusitis phenotypes

Background: Particulate matter ≤2.5 µm (PM2.5) exposure exacerbates inflammatory pathways associated with chronic rhinosinusitis (CRS). This study aimed to investigate the impact of PM2.5 exposure on tissue eosinophilia and the severity of CRS. Methodology: One hundred and twenty-nine patients with CRS were enrolled i...

A. Le Quoc · 0 citations
Open access Sep 2026

Effects of dupilumab on nasal mucociliary clearance in severe CRSwNP: evaluation of the saccharin test as an objective outcome measure.

Preliminary findings support the potential role of the saccharin test as a simple, objective tool for monitoring response to biologic therapy and support the potential role of the saccharin test as a simple, objective tool for monitoring response to biologic therapy.

G. Pagliuca, Veronica Clemenzi, S. Martellucci et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.